Hollow mesoporous silica nanoparticles for tumor vasculature targeting and PET image-guided drug delivery

被引：76
作者：
Chakravarty, Rubel [1 ,2 ]
Goel, Shreya [3 ]
Hong, Hao [1 ]
Chen, Feng [1 ]
Valdovinos, Hector F. [4 ]
Hernandez, Reinier [4 ]
Barnhart, Todd E. [4 ]
Cai, Weibo [1 ,3 ,4 ,5 ]
机构：
[1] Univ Wisconsin, Dept Radiol, Madison, WI 53792 USA
[2] Bhabha Atom Res Ctr, Isotope Prod & Applicat Div, Bombay 400085, Maharashtra, India
[3] Univ Wisconsin, Mat Sci Program, Madison, WI 53706 USA
[4] Univ Wisconsin, Dept Med Phys, Madison, WI 53705 USA
[5] Univ Wisconsin, Carbone Canc Ctr, Madison, WI 53792 USA
来源：
NANOMEDICINE | 2015年 / 10卷 / 08期
基金：
美国国家卫生研究院;
关键词：
cancer; hollow mesoporous silica nanoparticles; image-guided drug delivery; PET; positron emission tomography; theranostics; RADIOLABELED RGD PEPTIDES; INTEGRIN ALPHA(V)BETA(3); CANCER-THERAPY; BIOCOMPATIBILITY; EXPRESSION;
D O I：
10.2217/nnm.14.226
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Aim: Development of multifunctional and well-dispersed hollow mesoporous silica nanoparticles (HMSNs) for tumor vasculature targeted drug delivery and PET imaging. Materials & methods: Amine functionalized HMSNs (150-250 nm) were conjugated with a macrocyclic chelator, (S)-2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triaceticacid (NOTA), PEGylated and loaded with antiangiogenesis drug, Sunitinib. Cyclo(Arg-Gly-Asp-D-Tyr-Lys) (cRGDyK) peptide was attached to the nanoconjugate and radiolabeled with Cu-64 for PET imaging. Results: Cu-64-NOTA-HMSN-PEG-cRGDyK exhibited integrin-specific uptake both in vitro and in vivo. PET results indicated approximately 8% ID/g uptake of targeted nanoconjugates in U87MG tumors, which correlated well with ex vivo and histological analyses. Enhanced tumor-targeted delivery of sunitinib was also observed. Conclusion: We successfully developed tumor vasculature targeted HMSNs for PET imaging and image-guided drug delivery.
引用
收藏
页码：1233 / 1246
页数：14
相关论文
共 46 条
[11]   RGD-Based Strategies To Target Alpha(v) Beta(3) Integrin in Cancer Therapy and Diagnosis [J].
Danhier, Fabienne ;
Le Breton, Aude ;
Preat, Veronique .
MOLECULAR PHARMACEUTICS, 2012, 9 (11) :2961-2973
[12]   Cytotoxicity of mesoporous silica nanomaterials [J].
Di Pasqua, Anthony J. ;
Sharma, Krishna K. ;
Shi, Yan-Li ;
Toms, Bonnie B. ;
Ouellette, Wayne ;
Dabrowiak, James C. ;
Asefa, Tewodros .
JOURNAL OF INORGANIC BIOCHEMISTRY, 2008, 102 (07) :1416-1423
[13]   A cationic surfactant assisted selective etching strategy to hollow mesoporous silica spheres [J].
Fang, Xiaoliang ;
Chen, Cheng ;
Liu, Zhaohui ;
Liu, Pengxin ;
Zheng, Nanfeng .
NANOSCALE, 2011, 3 (04) :1632-1639
[14]   Imaging and cancer: A review [J].
Fass, Leonard .
MOLECULAR ONCOLOGY, 2008, 2 (02) :115-152
[15]   Theranostic Applications of Nanomaterials in Cancer: Drug Delivery, Image-Guided Therapy, and Multifunctional Platforms [J].
Fernandez-Fernandez, Alicia ;
Manchanda, Romila ;
McGoron, Anthony J. .
APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY, 2011, 165 (7-8) :1628-1651
[16]   Radiolabelled RGD peptides for imaging and therapy [J].
Gaertner, F. C. ;
Kessler, H. ;
Wester, H. -J. ;
Schwaiger, M. ;
Beer, A. J. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 :126-138
[17]   Targeting Multiplicity: The Key Factor for Anti-Cancer Nanoparticles [J].
Gary-Bobo, M. ;
Vaillant, O. ;
Maynadier, M. ;
Basile, I. ;
Gallud, A. ;
El Cheikh, K. ;
Bouffard, E. ;
Morere, A. ;
Rebillard, X. ;
Puche, P. ;
Nirde, P. ;
Garcia, M. .
CURRENT MEDICINAL CHEMISTRY, 2013, 20 (15) :1946-1955
[18]  
Gasparini G, 1998, CLIN CANCER RES, V4, P2625
[19]  
Haubner R, 2001, J NUCL MED, V42, P326
[20]   Positron emission tomography imaging of CD105 expression during tumor angiogenesis [J].
Hong, Hao ;
Yang, Yunan ;
Zhang, Yin ;
Engle, Jonathan W. ;
Barnhart, Todd E. ;
Nickles, Robert J. ;
Leigh, Bryan R. ;
Cai, Weibo .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (07) :1335-1343
12345